A66 is an inhibitor of p110α PI3K that exhibits anticancer chemotherapeutic activity. A66 decreases cell viability of endometrial cancer cells and inhibits tumor growth of xenografts when administered in combination with other therapies. In animal models, A66 increases glucose output and impairs glucose and insulin tolerance.
| Cas No. | 1166227-08-2 |
|---|---|
| Purity | ≥98% |
| Formula | C17H23N5O2S2 |
| Formula Wt. | 393.53 |
| IUPAC Name | (2S)-1-N-[5-(2-tert-butyl-1,3-thiazol-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A0002 Info Sheet PDF |
|---|---|
| Brochures | PI3K-Akt-mTORC Pathway Booklet |
Weigelt B, Warne PH, Lambros MB, et al. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.
Smith GC, Ong WK, Rewcastle GW, et al. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J. 2012 Feb 15;442(1):161-9. PMID: 22142257.
